Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some administration and safety-related statements are consistent with label excerpts (e.g., subcutaneous use only, self-administration requires training, avoid injecting irritated/bruised skin cannot be confirmed from provided excerpts). Several key pen-specific and injection-procedure claims are not supported by the supplied prescribing-information excerpts, and at least one critical labeling scope issue exists (self-injection wording does not distinguish adult vs pediatric caregiver limitation as precisely as label excerpt).
Category Scores
Accurate Statements
Cosentyx (secukinumab) is administered as a subcutaneous injection (under the skin).
Label excerpt 2.2: “UnoReady pen, Sensoready pen, and prefilled syringes are for subcutaneous use only.”
Cosentyx dosing depends on the condition being treated and the specific regimen prescribed.
Label excerpts 2.3, 2.4, 2.10: Recommended dosing differs by indication (e.g., plaque psoriasis vs psoriatic arthritis vs hidradenitis suppurativa).
Unsupported Statements
The Cosentyx pen is intended for self-injection by adults after training by a clinician.
Supported only in part: label excerpt 2.2 says adult patients may self-administer after proper training, but the claim does not reflect the label’s distinction that “Pediatric patients should not self-administer… An adult caregiver should prepare and inject…” (missing nuance).
Cosentyx pen should be taken out of the refrigerator and allowed to reach room temperature before injecting.
No refrigerator-to-room-temperature instruction is present in the provided excerpts.
Cosentyx can be injected into the thigh or the abdomen.
No labeled site-specific guidance (e.g., thigh/abdomen) is present in provided excerpts.
Cosentyx should not be injected into irritated or bruised skin.
No statement about avoiding irritated/bruised skin is present in provided excerpts.
Injection sites should be rotated each time.
No site-rotation instruction is present in provided excerpts.
The liquid in the pen should look as instructed in the pen materials, typically clear to slightly opalescent, and not discolored.
No pen-visual inspection criteria are present in the provided label excerpts.
Do not use the pen if it looks damaged or if the liquid does not look right.
No such pen-use/inspection instruction is present in the provided excerpts.
The injection site should be cleaned with an alcohol wipe and allowed to dry before injecting.
No label excerpt provided for skin disinfection or drying instructions.
The pen should be placed against the skin at the injection site as directed by the pen.
No such step-by-step pen technique guidance is present in the provided excerpts.
After pressing to start the injection, the pen should be kept in place until the dose is delivered as indicated by the pen instructions.
No such step-by-step administration timing instruction is present in the provided excerpts.
After injection, the pen should be removed and the site should not be rubbed.
No such post-injection instruction is present in the provided excerpts.
Used Cosentyx pens should be disposed of immediately in an approved sharps container.
No sharps disposal instruction is present in the provided excerpts.
If a dose is missed, the patient should contact their healthcare team to ask when to take the next dose.
No missed-dose guidance is present in the provided excerpts.
Patients should contact their clinician promptly if they get signs of a serious infection, such as fever or feeling very unwell.
The label excerpt 5.1 describes increased risk of infections, but the provided excerpts do not include patient counseling phrasing or specific symptoms (fever/unwell) as an instruction.
Patients should contact their clinician promptly if they have concerns about an injection reaction, such as swelling, hives, or trouble breathing.
Label excerpt 5.2 describes serious hypersensitivity reactions (anaphylaxis, angioedema, urticaria) and discontinuation and appropriate therapy if serious allergic reaction occurs, but the provided excerpts do not include this specific “promptly contact clinician for injection reaction” counseling wording or the specified symptom set in that form.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Important administration instruction that COSENTYX is for use under guidance and supervision of a healthcare provider (and that pediatric patients should not self-administer; adult caregiver must inject after proper training).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple pen-specific administration steps are not supported by the provided label excerpts (temperature equilibration, injection site selection/avoidance, rotation, visual inspection, skin prep, technique, disposal, missed dose counseling). While the overall subcutaneous/self-administration concept aligns with label excerpt 2.2, the unsupported procedural details could lead to inaccurate administration relative to label-approved instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Many administration/pen-use instructions are not supported by the provided FDA label excerpts; one claim also omits pediatric self-administration limitation nuance.
Suggested Improvement
Restrict administration instructions to those explicitly present in the provided label excerpts (not provided pen-visual, temperature, site, rotation, skin prep, or sharps disposal steps). Include the label’s pediatric limitation and caregiver training requirement from excerpt 2.2.